January 3, 2025

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials – The Lancet

January 3, 2025

Regenerative Medicine Offers Positive Results for Treating Vitiligo – Managed Healthcare Executive

January 3, 2025

Common biomarkers of idiopathic pulmonary fibrosis and systemic sclerosis based on WGCNA and machine learning – Nature

January 2, 2025

Metabolomic profiling of saliva from cystic fibrosis patients – Nature

January 2, 2025

Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis – Nature